UTMD · Current Report (Form 8-K) · Filed November 4, 2025

Utah Medical Products Inc — 8-K exhibit

utmd_ex99z1.htm

Utah Medical Products Inc on Boardroom Alpha

EXHIBIT 99.1

Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend

Contact: Brian KoopmanNovember 4, 2025

(801) 566-1200

Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors. Mr. Timken, who served as UTMD’s outside legal counsel for over twenty years prior to his retirement in 2025, graduated with a J.D. degree from the University of Utah College of Law in 1997. The Board believes his robust understanding of the functional and strategic challenges that the Company faces will be integral for continuing UTMD’s future excellent performance.

In addition, the Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025. This is a 1.6% increase over the prior regular quarterly cash dividend.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer